고령자용 건강 제품 시장 : 세계 예측(2026-2032년)

The Health Products for The Elderly Market is projected to grow by USD 4.53 billion at a CAGR of 6.45% by 2032.

Health Products for the Elderly: Executive Overview

Health products for the elderly encompass medicines, nutritional products, mobility aids, continence solutions, hearing and vision devices, home-care equipment, monitoring tools, and other products that support healthy ageing. Demand is shaped by longer life expectancy, the rising prevalence of chronic conditions, preference for independent living, caregiver needs, and expansion of care beyond hospitals. Product development increasingly emphasizes safety, usability, accessibility, affordability, and integration with clinical and social-care systems.

Ageing, Prevention, and Care-at-Home Are Reshaping the Landscape

The sector is shifting from episodic treatment toward prevention, functional maintenance, rehabilitation, and sustained support for daily living. Home-based care is gaining strategic importance as families, professional caregivers, and health systems seek to reduce avoidable institutional care while improving continuity. Buyers are placing greater emphasis on simple instructions, ergonomic design, adherence support, culturally appropriate nutrition, and interoperability with existing care pathways. Regulatory scrutiny is also intensifying around product claims, evidence quality, cybersecurity, accessibility, and responsible use of personal health data.

Artificial Intelligence Is Improving Personalization, Monitoring, and Operational Decisions

Artificial intelligence is contributing to risk identification, symptom monitoring, medication-adherence support, fall detection, demand planning, and personalization of nutrition and rehabilitation programs. Its value is strongest when outputs are explainable, clinically supervised, and connected to clear intervention protocols. Adoption remains constrained by uneven data quality, privacy requirements, digital literacy, bias risks, procurement complexity, and the need to preserve human oversight. Industry leaders should treat AI as an augmentation capability rather than a substitute for clinicians, caregivers, or informed patient choice.

Regional Insights: Access, Care Models, and Regulation Drive Divergent Priorities

North America emphasizes home care, chronic-condition management, connected monitoring, and reimbursement alignment, while affordability and unequal access remain important considerations. Europe places strong weight on healthy ageing, social-care coordination, accessibility, privacy, and evidence-based procurement. Asia-Pacific combines rapid ageing in several economies with varied income levels, creating demand for both advanced connected products and lower-cost, easy-to-use solutions. Latin America is shaped by uneven healthcare access, family-centered caregiving, and the need for durable products distributed through diverse channels. The Middle East is investing in healthcare modernization and home-based support, with localization and workforce capability influencing adoption. Africa presents substantial needs in affordable assistive products, primary-care integration, supply reliability, and caregiver training.

Group Insights: Economic and Institutional Blocs Have Distinct Priorities

ASEAN markets commonly prioritize affordability, scalable distribution, community care, and products suitable for multigenerational households. BRICS economies reflect varied healthcare capacity but share opportunities in chronic-care support, local manufacturing, and adaptable assistive technologies. The European Union emphasizes harmonized safety requirements, data protection, accessibility, and coordination between health and social-care systems. G7 markets generally have mature clinical infrastructures and strong demand for home care, prevention, and digitally enabled services, alongside rigorous evidence expectations. GCC countries are characterized by healthcare modernization, investment in specialized services, and interest in technology-enabled ageing support. NATO members, considered as a broad institutional grouping, show diverse national systems but commonly prioritize resilience of medical supply chains, interoperability, preparedness, and care continuity.

Country Insights: National Demographics and Health Systems Shape Product Fit

Australia combines ageing-related demand with a large geography that increases the value of home support, telehealth, and reliable distribution. Brazil requires products that address regional inequality, chronic disease, and family caregiving. Canada places importance on community care, accessibility, and solutions suited to dispersed populations. China is expanding support for older adults while balancing urban innovation with broad affordability and service coverage. France and Germany emphasize regulated quality, rehabilitation, home care, and coordination across health and social services. India presents strong potential for affordable, durable, multilingual, and low-connectivity solutions. Italy and Spain face significant ageing and family-care pressures, supporting demand for prevention, mobility, nutrition, and home assistance. Japan has advanced ageing-related needs and strong interest in robotics, monitoring, ergonomics, and independent living. Mexico requires accessible products that can function across varied healthcare and income environments. Russia's priorities include continuity of supply, chronic-care support, and regional service access. South Korea is combining digital health capability with rapidly intensifying ageing needs. The United Kingdom emphasizes integrated care, social-care capacity, evidence, and procurement value. The United States has substantial demand for chronic-care management, home-based services, accessibility, and digitally supported monitoring, with coverage and affordability influencing uptake.

Strategic Priorities for Leaders in Elder-Care Products

Leaders should segment offerings by functional need, care setting, caregiver role, and purchasing pathway rather than treating older adults as a single customer group. Design products with large-format information, intuitive controls, low physical strain, multilingual support, and clear safety guidance. Build evidence around outcomes that matter to users and payers, including adherence, independence, preventable complications, caregiver burden, and quality of life. Strengthen partnerships across clinicians, pharmacies, community organizations, distributors, and social-care providers. Establish privacy-by-design and human oversight for AI-enabled products, while preparing resilient sourcing, repair, training, and after-sales support. Regional adaptation should address reimbursement, regulation, infrastructure, cultural expectations, and affordability before expansion.

Research Methodology: Evidence-Led Market Interpretation

This executive summary applies a structured qualitative synthesis of verified public evidence relevant to ageing, healthcare delivery, assistive technology, consumer health, medical-device regulation, digital health, and social-care systems. The assessment compares demographic conditions, disease and functional needs, care settings, policy environments, technology readiness, distribution constraints, and affordability considerations across the required regions, groups, and countries. Claims are framed at the level supported by established evidence; no market estimates, market shares, forecasts, or company-specific assessments are used. Regional and country comparisons should be validated against current national statistics, regulatory publications, clinical guidance, procurement rules, and peer-reviewed research before operational decisions are made.

Conclusion: Build Accessible, Evidence-Based Products Around Independent Ageing

The health-products landscape for older adults is moving toward integrated support for prevention, independence, chronic-condition management, rehabilitation, and care at home. Successful offerings will combine clinical credibility with practical usability, affordability, dependable distribution, and strong caregiver support. Artificial intelligence can improve responsiveness and personalization when governed responsibly, but trust, accessibility, and human supervision remain essential. Leaders that align product design and partnerships with local health-system realities will be better positioned to improve outcomes across diverse ageing populations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Health Products for The Elderly Market, by Product Category

• 7.1. Introduction
• 7.2. Diagnostic Devices
  • 7.2.1. Blood Pressure Monitors
  • 7.2.2. Glucometers
  • 7.2.3. Pulse Oximeters
• 7.3. Home Health Monitoring
  • 7.3.1. Remote Patient Monitoring
  • 7.3.2. Smart Sensors
  • 7.3.3. Telehealth Platforms
• 7.4. Incontinence Products
  • 7.4.1. Adult Diapers
  • 7.4.2. Bed Pads
  • 7.4.3. Protective Underwear
• 7.5. Mobility Aids
  • 7.5.1. Canes
  • 7.5.2. Stair Lifts
  • 7.5.3. Walkers
    • 7.5.3.1. Rollators
    • 7.5.3.2. Standard Walkers
  • 7.5.4. Wheelchairs
• 7.6. Nutritional Supplements
  • 7.6.1. Herbal Supplements
  • 7.6.2. Minerals
  • 7.6.3. Protein Supplements
  • 7.6.4. Vitamins
    • 7.6.4.1. Vitamin B Complex
    • 7.6.4.2. Vitamin C
    • 7.6.4.3. Vitamin D
• 7.7. Orthopedic Supports
  • 7.7.1. Braces
  • 7.7.2. Insoles
  • 7.7.3. Splints
• 7.8. Personal Care Products
  • 7.8.1. Bath Safety
  • 7.8.2. Oral Care
  • 7.8.3. Skin Care

8. Health Products for The Elderly Market, by User Type

• 8.1. Introduction
• 8.2. Elderly Individuals
• 8.3. Informal Caregivers
• 8.4. Professional Care Providers
• 8.5. Institutional Buyers

9. Health Products for The Elderly Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Home Healthcare Provider
  • 9.2.1. Agency Based Providers
  • 9.2.2. Independent Contractors
• 9.3. Hospital Channel
  • 9.3.1. Private Hospital
  • 9.3.2. Public Hospital
• 9.4. Online Pharmacy
  • 9.4.1. Brand Website
  • 9.4.2. Third Party Marketplace
• 9.5. Retail Pharmacy

10. Health Products for The Elderly Market, by Region

• 10.1. Introduction
• 10.2. Asia-Pacific
• 10.3. North America
• 10.4. Latin America
• 10.5. Europe
• 10.6. Middle East
• 10.7. Africa

11. Health Products for The Elderly Market, by Group

• 11.1. Introduction
• 11.2. ASEAN
• 11.3. GCC
• 11.4. European Union
• 11.5. BRICS
• 11.6. G7
• 11.7. NATO

12. Health Products for The Elderly Market, by Country

• 12.1. Introduction
• 12.2. United States
• 12.3. Canada
• 12.4. Mexico
• 12.5. Brazil
• 12.6. United Kingdom
• 12.7. Germany
• 12.8. France
• 12.9. Russia
• 12.10. Italy
• 12.11. Spain
• 12.12. China
• 12.13. India
• 12.14. Japan
• 12.15. Australia
• 12.16. South Korea

13. Competitive Landscape

• 13.1. Market Share Analysis, 2025
• 13.2. Market Concentration Analysis, 2025
  • 13.2.1. Concentration Ratio (CR)
  • 13.2.2. Herfindahl Hirschman Index (HHI)
• 13.3. Recent Developments & Impact Analysis, 2025
• 13.4. Product Portfolio Analysis, 2025
• 13.5. Benchmarking Analysis, 2025

14. Company Profiles

• 14.1. Abbott Laboratories
• 14.2. Arjo AB
• 14.3. Baxter International Inc.
• 14.4. Becton, Dickinson and Company
• 14.5. Boston Scientific Corporation
• 14.6. Cardinal Health Inc.
• 14.7. Coloplast A/S
• 14.8. Fresenius Medical Care AG & Co. KGaA
• 14.9. GE HealthCare Technologies Inc.
• 14.10. Hindustan Syringes & Medical Devices Limited
• 14.11. Johnson & Johnson
• 14.12. Koninklijke Philips N.V.
• 14.13. Medtronic plc
• 14.14. Nestle S.A.
• 14.15. Novartis AG
• 14.16. Otsuka Pharmaceutical Co., Ltd.
• 14.17. Poly Medicure Limited
• 14.18. ResMed Inc.
• 14.19. Siemens Healthineers AG
• 14.20. Stryker Corporation

15. Key Experts